Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the...
34 insider purchases on record · latest filing 2024-09-24.
Insiders have also filed 17 sale transactions at CAPR.